<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03192657</url>
  </required_header>
  <id_info>
    <org_study_id>ADM01</org_study_id>
    <nct_id>NCT03192657</nct_id>
  </id_info>
  <brief_title>Basiliximab Treating Interstitial Pneumonia of CADM</brief_title>
  <official_title>Basiliximab as a Treatment of Interstitial Pneumonia in Clinical Amyopathic Dermatomyositis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 52-week, randomized, open and routine treatment controlled study. This study will
      assess the safety and efficacy of basiliximab as an add-on treatment for interstitial
      pneumonia in clinical amyopathic dermatomyositis (CADM) patients. 100 CADM patients are
      planned to be enrolled in a single center.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>52 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced vital capacity</measure>
    <time_frame>52 week</time_frame>
    <description>measured with lung function test equipment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total lung capacity</measure>
    <time_frame>52 week</time_frame>
    <description>measured with lung function test equipment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diffusing capacity</measure>
    <time_frame>52 week</time_frame>
    <description>transfer factor of the lung for carbon monoxide, measured with lung function test equipment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung CT change</measure>
    <time_frame>52 week</time_frame>
    <description>Patient lung high resolution CT images will be semi-quantitatively assessed. Changes over baseline and endpoint will be then calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum ferritin</measure>
    <time_frame>52 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum KL-6</measure>
    <time_frame>52 week</time_frame>
    <description>A new biomarker of alveolar injury.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Lung; Disease, Interstitial, With Fibrosis</condition>
  <condition>Dermatomyositis</condition>
  <arm_group>
    <arm_group_label>Basiliximab group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Basiliximab: 20mg injection each time at day1 and day5, respectively. The first administration should be within 8 weeks after disease onset.
Calcineurin inhibitors: cyclosporin A 3-5mg/kg/d or tacrolimus 0.05-0.10mg/kg/d.
Steroids: 1mg/kg/d, calculated with prednisone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcineurin inhibitors: cyclosporin A 3-5mg/kg/d or tacrolimus 0.05-0.10mg/kg/d.
Steroids: 1mg/kg/d, calculated with prednisone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basiliximab</intervention_name>
    <description>The first administration should be within 8 weeks after disease onset.</description>
    <arm_group_label>Basiliximab group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcineurin Inhibitors</intervention_name>
    <description>Researchers can choose cyclosporin A or tacrolimus according to patient tolerance. Either agent should be applied promptly once infection is ruled out for a patient.</description>
    <arm_group_label>Basiliximab group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Steroids</intervention_name>
    <description>Dosage of steroid can be adjusted according to personal experience of the researcher.</description>
    <arm_group_label>Basiliximab group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fulfill Sontheimer-Bohan-Peter diagnosis criteria for dermatomyositis.

          -  Agreement of contraception.

          -  Serum creatine Kinase ≤ 1.5 fold of upper normal level.

          -  Interstitial pneumonia:

        (meet at least two in four of following)

          1. interstitial pneumonia images in high resolution CT;

          2. DLCO (diffusing capacity)≤ 60% predict in lung function test;

          3. elevated serum KL-6;

          4. serum anti-MDA5 (+).

        Exclusion Criteria:

          -  Previous application of immunosuppressives or any target treatment for
             dermatomyositis.

          -  Clinically significant active infection including ongoing and chronic infections
             History of human immunodeficiency virus (HIV).

          -  Confirmed Positive tests for hepatitis B or positive test for hepatitis C Active
             tuberculosis.

          -  Abnormal renal function at screening (serum creatine＞300μmol/L，or
             eGFR＜60mL/min/1.73m2, or end-stage renal disease).

          -  Abnormal liver function test at screening (ALT, AST or total bilirubin over 2 fold of
             upper normal level.

          -  History of any malignancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>RenJi Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2017</study_first_submitted>
  <study_first_submitted_qc>June 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2017</study_first_posted>
  <last_update_submitted>June 18, 2017</last_update_submitted>
  <last_update_submitted_qc>June 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Dermatomyositis</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

